Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Key points are not available for this paper at this time.
Abstract
Supplementary Figure 3. Activity of osimertinib in EGFR 19Del-derived BBT-176-resistant clones. Abbreviation: BR(1/2), BBT-176-resistant (clone 1/2).
AIに質問
Like
Bookmark
Share
View Full Paper
AIに質問
Like
Bookmark
Share
View Full Paper
Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer | Synapse